First reported 22 hours ago -
Updated 22 hours ago -
European regulators have for the first time recommended approval of Eli Lilly
’s Abasaria, a bio-similar version of Sanofi’s Lantus, which generates approximately $8 billion in yearly sales, as reported in Yahoo!7 News. The European Medicines Agency (EMA), ...
[Published FirstWord Pharma - 22 hours ago]